Table 1.
Baseline characteristics
| N (%) | |
|---|---|
| Number of Pts. | 12 |
| Age, median (range) | 55 (40, 66) |
| Sex, Female | 6 (50) |
| Type of Follicular Lymphoma | |
| Relapsed | 10 (83) |
| Transformed | 2 (17) |
| FL Stage at Diagnosis | |
| I | 0 (0) |
| II | 1 (8) |
| III | 4 (33) |
| IV | 7 (58) |
| FL Stage at Transplant | |
| I | 0 (0) |
| II | 1 (8) |
| III | 4 (33) |
| IV | 7 (58) |
| Status at Transplant Conditioning | |
| CR | 0 (0) |
| PR | 7 (58) |
| Refractory | 5 (42) |
| No. of Prior Therapies before RIT, median (range) | 5 (2, 10) |
| Prior Autologous Transplant | 1 (8) |
| Karnofsky Performance Status | |
| 70 | 2 (16) |
| 80 | 5 (42) |
| 90 | 4 (32) |
| 100 | 1 (8) |
| Time from RIT to Allotransplant in mos., median (range) | 1.0 (0.4, 5.8) |
| HLA Matched (A, B, DR)/Donor Type | |
| Matched Unrelated | 4 (33) |
| Matched Related | 3 (25) |
| Mismatched Unrelated* | 4 (33) |
| Double umbilical cord blood | 1(8) |
| CMV | |
| Donor −/Recipient − | 4 (33) |
| Donor −/Recipient + | 1 (8) |
| Donor +/Recipient − | 4 (33) |
| Donor +/Recipient + | 3 (25) |
| Stem Cell Source | |
| PBSC | 11 (92) |
| Cord Blood | 1 (8) |
| Type of Conditioning | |
| Busulfan/Fludarabine | 11 (92) |
| Melphalan/Fludarabine/ATG | 1 (8) |
| GVHD Prophylaxis | |
| Tacrolimus/mini-methotrexate | 4 (33) |
| Tacrolimus/Sirolimus/mini-methotrexate | 1 (8) |
| Tacrolimus/Sirolimus | 2 (16) |
| Tacrolimus/Bortezomib/mini-methotrexate | 3 (25) |
| Sirolimus/Mycophenolate mofetil | 2 (16) |
| CD34 dose × 106/kg (median, range). n = 9 | 6.42 (5.81) |
*
Three patients had one antigen mismatch and one had two antigen mismatches